Company: NCEL
Filing Date: 2025-03-31
Form Type: 425
Source: 0001213900-25-025889
Chunk: 259

Company: NewcelX Ltd.
Filing Date: 2025-03-31
Form: 425
Chunk 259
---
 Kadimastem are using forward-looking statements
when they discuss the potential second closing of the equity financing, the expected use of proceeds from the offerings, the expected
closing of the merger, the timing of the closing of the transaction and the potential benefits of the transaction to NLS and Kadimastem
and their respective shareholders, as well as the expected strategic position of the combined company following the merger, if completed,
and the plan to prepare and initiate a Phase IIa multi-site clinical trial of AstroRx®, Kadimastem’s product candidate for Amyotrophic
Lateral Sclerosis (ALS), and that the funding of the $3 million equity financing and $25 million equity facility agreement will support
the merger with Kadimastem. These forward-looking statements and their implications are based on the current expectations of the management
of NLS only and are subject to a number of factors and uncertainties that could cause actual results to differ materially from those described
in the forward-looking statements. The following factors, among others, could cause actual results to differ materially from those described
in the forward-looking statements: changes in technology and market requirements; NLS may encounter delays or obstacles in launching and/or
successfully completing its clinical trials; NLS products may not be approved by regulatory agencies, NLS technology may not be validated
as it progresses further and its methods may not be accepted by the scientific community; NLS may be unable to retain or attract key employees
whose knowledge is essential to the development of its products; unforeseen scientific difficulties may develop with NLS’ process;
NLS’ products may wind up being more expensive than it anticipates; results in the laboratory may not translate to equally good
results in real clinical settings; results of preclinical studies may not correlate with the results of human clinical trials; NLS patents
may not be sufficient; NLS products may harm recipients; changes in legislation may adversely impact NLS; inability to timely develop
and introduce new technologies, products and applications; and loss of market share and pressure on pricing resulting from competition,
which could cause the actual results or performance of NLS to differ materially from those contemplated in such forward-looking statements.
Except as otherwise required by law, NLS undertakes no obligation to publicly release any revisions to these forward-looking statements
to reflect events or circumstances after the date hereof or to reflect the occurrence of unanticipated events. More detailed information
about the risks and uncertainties affecting NLS is contained under the heading “Risk Factors” in NLS